Gilead Sciences Inc (BSP:GILD34)
R$ 260.26 -0.46 (-0.18%) Market Cap: 650.76 Bil Enterprise Value: 769.98 Bil PE Ratio: 109.37 PB Ratio: 6.11 GF Score: 71/100

Gilead Sciences Inc at Barclays Global Healthcare Conference Transcript

Mar 13, 2024 / 03:15PM GMT
Release Date Price: R$186.39
Carter Lewis Gould
Barclays Bank PLC, Research Division - Senior Analyst

Good afternoon, and welcome to Day 2 of the Barclays Global Healthcare Conference. My name is Carter Gould, covering U.S. Biopharma. I am pleased to welcome Gilead Sciences to the stage. Joining us from the company, Andy Dickinson, CFO. Andy, you're going to make some opening comments, and then we'll launch in the Q&A.

Andrew D. Dickinson
Gilead Sciences, Inc. - Executive VP & CFO

Great. Thanks. Thank you for having us, and thanks for joining the presentation. Look, at a high level, I'd say it's an exciting period for Gilead. We're moving into kind of the second stage of the restructuring expansion of the company. We have a number of growth opportunities, and we expect accelerating growth through the end of the decade. So as most of you know, we have the world's largest HIV business, stable, growing, long-term patent protection and a number of product launches that are coming between now and the end of the decade that should drive additional growth.

We have the world's

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot